ABSTRACT
Introduction
Anthracyclines (daunomycin, doxorubicin, epirubicin, idarubicin) are among the most effective antineoplastic drugs and have gained widespread use in the treatment of numerous solid tumors and hematological malignancies. These drugs belong to the class of antineoplastic antibiotics which interfere with cell replication, by acting on DNA at several levels showing an effect in every phase of the cell cycle. Doxorubicin and daunomycin (figure 1) are the more commonly used anthracyclines in clinical practice; they are administered only by intravenous infusion and metabolized by the liver. Their main route of excretion is through bile, while urinary elimination accounts for approximately 1/6 of the total amount. Although anthracyclines exhibit a range of toxic effects including myelosuppression, mucositis and hair loss, cardiotoxicity may be permanent and progressive.
Therefore, the oncologist should take into account the risk of cardiac toxicity due to anthracyclines as a potential cause of severe morbidity in survivors of childhood cancers, as children will have a chance of long-term survival once cured from cancer. We reviewed Doxorubicin Daunomycin the spectrum of clinical presentations of anthracycline-induced toxicity, focusing on acute heart failure. (13, 16) and anthracycline infusions were used in order to lower peak drug concentration, reducing cardiotoxicity. Hypertension and any significant preexisting cardiac disease increase the 
Mechanism of cardiotoxicity

Clinical presentation
The clinical presentation of anthracycline-induced toxicity can be divided into: -acute or subacute: heart damage that develops immediately after the infusion of the drug or within a week of therapy -early onset chronic progressive cardiotoxicity: a depression of myocardial function which occurs during the treatment or within the first year after treatment -late onset chronic progressive cardiotoxicity: this occurs at least 1 year after the end of treatment. Clinically significant cardiotoxicity during or in the first year following initial chemotherapy is rare, occurring in less than 1% of children. (13) Acute heart failure related to anthracycline induced cardiotoxicity Acute heart failure in children receiving anthracyclines can occur within one week of drug infusion, thus without the presence of chronic cardiac damage, or as acute decompensated heart failure in the setting of established anthracycline-induced cardiomyopathy. The second scenario is more common and develops when underlying compensatory mechanisms that sustain normal cardiac function in the setting of chronic heart failure, are exhausted. Acute changes during anthracycline infusion range from minor electrocardiographic abnormalities (non-specific ST-T changes and QT prolongation) to fatal ventricular arrhythmias. Echocardiography can reveal LV systolic dysfunction that is usually transient, but a few patients may experience acute and potentially fatal congestive heart failure while on therapy. (25) In its more extreme form, this acute injury can include a pericarditis-myocarditis syndrome with onset of fever, pericarditis and congestive heart failure. This syndrome can occur at low cumulative doses of doxorubicin and can have a fatal outcome. (26) The Ross Classification (27) was developed for grading heart failure in infants and younger children (Grade I: asymptomatic. Grade II: mild tachypnea or diaphoresis with feeding in infants; dyspnea on exertion in older children. Grade III: marked tachypnea or diaphoresis with feeding in infants; prolonged feeding times with growth failure due to heart failure; in older children, marked dyspnea on exertion. Grade IV: symptoms such as tachypnea, retractions, grunting, or diaphoresis at rest). Breathlessness, a cardinal manifestation of left ventricular failure, may present, in order of severity, as: -exertional dyspnea (as left ventricular failure progresses, the intensity of exercise resulting in breathlessness declines progressively) -orthopnea (dyspnoea that develops in the recumbent position and is relieved by elevation of the head with pillows) -paroxysmal nocturnal dyspnoea (feeling of severe anxiety and suffocation and gasps for breath) -acute pulmonary edema (is considered a clinical emergency and occurs as initial presentation of heart failure or as an aggravating condition of heart failure. Presents as extreme breathlessness that develops suddenly, the respiratory rate is elevated, the alae nasi are dilated and there is inspiratory retraction of the intercostal space and use of accessory muscles of respiration; the skin is usually cold and cyanotic reflecting low cardiac output. On auscultation there are many lung sounds with ronchi, wheezes and fine crepitant rales that appear at first over the lung bases but then extend upward to the apices; cardiac auscultation is difficult because of the respiratory sounds).
Cardiomegaly occurs in patients with chronic systolic heart failure. Also, protodiastolic sounds (gallop sounds) are audible in patients with heart failure. In mild right-sided heart failure, the jugular venous pressure may be normal at rest but rises to abnormal levels with compression of the right upper quadrant (hepatojugular reflux). The liver often enlarges before overt edema develops and it may remain so even after other symptoms of rightsided heart failure have disappeared.
Although a cardinal manifestation of heart failure, edema does not correlate well with the level of systemic venous pressure. Edema in heart failure is usually symmetrical and pitting and generally occurs in the dependent portions of the body. Late in the course of heart failure, edema becomes massive and generalized (anasarca) and weight gain associated with anasarca correlates with attenuation of electrocardiographic voltage.
In severe heart failure prolonged sodium restriction coupled with intensive diuretic therapy and the inability to excrete free water, may lead to dilutional hyponatremia. 
